A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival at 9 months.
9 months of treatment
No
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim Pharmaceuticals
Hungary: National Institute of Pharmacy
1199.26
NCT01024920
December 2009
January 2014
Name | Location |
---|